Mini-Oral Session

[MO21] Mini-Oral Session 21　Gastrointestinal Cancer 2（Upper GI Tract 2）
【E】

Fri. Feb 18, 2022 2:05 PM - 2:55 PM Room 4 (Room A, 2F, Kyoto International Conference Center)

Chair：Hiroshi Imazeki（Clinical Trial Promotion Department, Chiba Cancer Center），Hitoshi Kusaba（Department of Medicine and Comprehensive Biosystemic Science, Kyushu University）

+Add all to schedule

[MO21-1] FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

^○Yue Wang¹, Tao Shi¹, Xuan Wang², Jinwei Hu³, Lixia Yu¹, Qin Liu¹, Nandie Wu¹, Baorui Liu¹, Jia Wei¹ (1.The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 2.The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, 3.OrigiMed)

[MO21-2] Correlation of response following NACT between FDG PETCT and TRG in SCC of esophagus A prospective study

^○Naveen Kumar¹, Svs Deo¹, Sandeep Bhoriwal¹, Amitabh Mondal¹, Atul Sharma², Raja Pramanik², Rakesh Kumar³, Sunil Kumar¹ (1.Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India, 2.Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India, 3.Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India)

[MO21-3] Altered fecal microbiota signatures in patients with anxiety and depression in the gastrointestinal cancer screening

^○Juan Zhu, Minjuan Li, Shanrui Ma, Wenqiang Wei (National Cancer Registry Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)

[MO21-4] Microbial Biomarker and Epidemiological Factor to Identify Esophageal Squamous Cell Carcinoma and Precancerous Lesions

^○Minjuan Li, Wenqiang Wei (National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)

[MO21-5] Association of CD4/CD8 ratio with survival and response to ICIs in patients with advanced gastric and esophageal cancer

^○Junjie Hang¹, Shuangwei Xu², Lixia Wu³ (1.Department of Medical Oncology, Changzhou No.2 People's Hospital, 2.Nanchang University, 3.Department of Medical Oncology, Shanghai Jing An District Zhabei Central Hospital)

[MO21-6] Decrease of soluble CTLA4 is a significant better prognostic marker in nivolumab treatment of advanced gastric cancer

^○Kotoe Oshima¹, Hirokazu Shoji¹, Chie Kudo-Saito², Hidekazu Hirano¹, Satoru Iwasa¹, Natsuko Okita¹, Atsuo Takashima¹, Narikazu Boku^1,3, Ken Kato^1,4 (1.Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 2.Department of Immune Medicine, National Cancer Center Research Institute, 3.Department of Medical Oncology and General Medicine, IMS Hospital, Institute of Medical Science, University of Tokyo, 4.Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)